Revolution Medicines, Inc. filings document a late-stage clinical oncology company focused on RAS-addicted cancers and RAS(ON) inhibitors. Its Form 8-K reports include financial results, clinical-program updates for daraxonrasib and other pipeline candidates, regulatory-related disclosures and material events tied to corporate progress.
The company’s SEC record also covers proxy governance, annual meeting matters, executive compensation, registered securities and capital-structure changes. Disclosures identify Nasdaq-listed common stock and warrants, and material-agreement filings describe convertible senior notes due 2033, related indenture terms and other financing arrangements used to support research and development, administrative expenses and potential commercialization activities.
Revolution Medicines insider sale to cover RSU taxes — The company's President of Research and Development, Stephen Michael Kelsey, reported a sale of 5,367 shares of common stock at $45.8249 per share executed under a Rule 10b5-1 plan to satisfy tax withholding on restricted stock unit vesting. After the transaction the filing reports beneficial ownership of 284,047 shares, which includes 84,000 RSUs. The sale is described as pursuant to a pre-existing 10b5-1 instruction adopted in May 2023.
Margaret A. Horn, Chief Operating Officer and Director of Revolution Medicines, reported a sale of 4,775 shares of the issuer's common stock on 09/16/2025 at a reported price of $45.8249 per share. After the transaction she beneficially owns 145,900 shares, which the filing states includes 70,500 restricted stock units (RSUs). The sale was executed under a Rule 10b5-1 instruction letter adopted May 31, 2023, to satisfy the reporting person's tax withholding obligations upon RSU vesting after July 15, 2023. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Horn on 09/18/2025.
Insider sale to cover taxes: This Form 4 shows Jeff Cislini, General Counsel of Revolution Medicines, executed a sale of 1,869 shares of common stock on 09/16/2025 at $45.8249 per share under a Rule 10b5-1 plan adopted May 31, 2023 to satisfy tax withholding for vested restricted stock units (RSUs). After the transaction he beneficially owns 52,224 shares, which includes 43,910 RSUs. The filing was signed by an attorney-in-fact on 09/18/2025. The disclosure is a routine insider tax-withholding sale rather than a discretionary trade.
Revolution Medicines insider sale to cover tax withholding following RSU vesting. Chief Financial Officer Jack Anders reported a sale of 2,320 shares of Revolution Medicines common stock on 09/16/2025 at an average price of $45.8249 per share, executed under a pre-existing Rule 10b5-1 instruction adopted May 31, 2023 to satisfy tax withholding obligations tied to RSU vesting after July 15, 2023. After the transaction Mr. Anders beneficially owned 110,994 shares, which the filing notes includes 48,275 restricted stock units. The Form 4 is signed and dated 09/18/2025.
Revolution Medicines, Inc. (RVMD) Form 144 discloses a proposed sale of 2,131 shares of common stock through ETRADE with an aggregate market value of $99,198.05, with an approximate sale date of 09/15/2025 on NASDAQ. The securities originated from restricted stock unit grants received from the issuer on 05/01/2023 (1,253 shares), 03/01/2024 (412 shares) and 03/01/2025 (466 shares), each noted as payment for services rendered. The filing also reports a prior sale by the same person of 2,173 shares on 06/16/2025 generating $86,550.59. The filer certifies no undisclosed material adverse information is known.
Revolution Medicines, Inc. (RVMD) Form 144 summary: The filing notifies a proposed sale of 5,296 shares of common stock with an aggregate market value of $246,528.80. The company reports 186,933,190 shares outstanding. The shares to be sold were granted as restricted stock units on 03/01/2022 (1,232), 03/01/2023 (1,270), 03/01/2024 (1,632) and 03/01/2025 (1,162), each described as payment for services.
The filing also discloses past sales by the same person over the past three months totaling 129,289 shares for aggregate gross proceeds of $5,728,585.16. The listed broker for the proposed sale is ETRADE and the approximate sale date is 09/15/2025 on NASDAQ. The filer attests there is no undisclosed material adverse information.
Revolution Medicines, Inc. (RVMD) filing a Form 144 notifies the SEC of a proposed sale of 4,712 shares of common stock, with an aggregate market value of $219,343.60, expected to be sold around 09/15/2025 on NASDAQ. The shares were received as restricted stock unit grants issued on 03/01 of 2022, 2023, 2024 and 2025 totaling 4,712 shares acquired for services rendered. The filer also reported a recent sale on 06/16/2025 of 3,510 shares for gross proceeds of $139,803.30. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and references Rule 10b5-1 trading plan disclosure if applicable.
Revolution Medicines (RVMD) Form 144 reports a proposed sale of 13,236 shares of common stock through ETRADE with an aggregate market value of $616,135.80, scheduled approximately on 09/15/2025 and to be executed on Nasdaq. The filing lists four prior restricted stock unit grants acquired on 03/01/2022, 03/01/2023, 03/01/2024 and 03/01/2025 totaling 13,136 shares received for services. It also discloses a sale by the same person on 06/16/2025 of 13,496 shares for gross proceeds of $537,545.68. The filer certifies no undisclosed material information.
Revolution Medicines (RVMD) filed a Form 144 notice for the proposed sale of 1,842 shares of common stock to be executed through ETRADE with an aggregate market value of $85,745.10. The filing shows the shares were acquired as restricted stock unit grants between 03/01/2022 and 03/01/2025 in five tranches totaling 1,842 shares, with the planned approximate sale date of 09/15/2025 on NASDAQ. The filer also reported two prior sales in the past three months by Jeff Cislini: 1,878 shares on 06/16/2025 for $74,800.74 and 1,912 shares on 06/20/2025 for $75,735.85. The filing lists total shares outstanding as 186,933,190, indicating the position is small relative to the company’s outstanding stock.
Insider transactions by Stephen Michael Kelsey at Revolution Medicines (RVMD) show option exercises and systematic sales under a 10b5-1 plan adopted February 28, 2025. On September 11 and September 15, 2025, the reporting person acquired stock options exercisable at $4.73 (100,000 and 25,000 options) and sold portions of common stock in multiple trades at weighted average sale prices reported as $43.5771, $44.4847, $45.9175 and $46.9302. The filing reports beneficial ownership of 289,414 shares of common stock (direct) following the transactions and includes restricted stock units of 94,426 within holdings. The transactions were executed pursuant to the 10b5-1 plan and were signed by an attorney-in-fact on behalf of the reporting person.